Form 4: Agios Pharmaceuticals Director Acquires Shares

Agios Pharmaceuticals Director Jeffrey D. Capello acquired 1,976 shares of common stock through restricted stock units, increasing his beneficial ownership.

Summary

• Director Jeffrey D. Capello acquired 1,976 shares of Agios Pharmaceuticals, Inc. common stock on June 13, 2026.
• The acquisition was made through restricted stock units (RSUs) with no purchase price indicated.
• Following this transaction, Mr. Capello beneficially owns 8,049 shares of common stock.
• The RSUs were granted on June 13, 2023, and will vest in three equal annual installments starting June 13, 2024.
• Vested shares will be delivered within three business days of vesting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as director share acquisitions can indicate confidence, but the transaction is part of a pre-existing compensation plan.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The vesting schedule indicates a long-term commitment to the company by the director.

Future Outlook

The restricted stock units will vest in three equal annual installments starting June 13, 2024, with vested shares to be delivered within three business days after vesting.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are closely watched by the market as potential indicators of management's view on the company's valuation and future performance within the biopharmaceutical sector.

Stakeholder Impact

• Shareholders: May view director's acquisition positively as a sign of commitment and confidence.
• Employees: The transaction is part of a compensation structure that may be mirrored for other employees.
• Management: Reinforces the alignment of director interests with those of shareholders.

Next Steps

• Vesting of remaining restricted stock units in two equal annual installments.
• Delivery of vested shares to the reporting person within three business days of vesting.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Acquisition, Restricted Stock Units, Beneficial Ownership, Agios Pharmaceuticals, Director